Globus Medical Q2 Earnings Call Highlights

Globus Medical Q2 revenue rose 6% to $789.6 million, while record non-GAAP EPS increased 56% to $1.34 and adjusted EBITDA margin expanded to 35.4%. Spine and trauma growth offset declines in enabling technologies and Nevro. Musculoskeletal revenue grew 8%, led by 7% U.S. spine growth, 12% constant-currency international spine growth and a 31% increase in trauma revenue. Robotic-equipment placements also increased despite lower reported enabling-technologies revenue as the company shifts toward leasing and rental models. Globus reaffirmed 2026 revenue guidance of $3.18 billion to $3.22 billion but raised its adjusted EPS outlook to $4.95-$5.05. The company also repurchased $136.1 million of stock during the quarter, while continuing efforts to improve Nevro’s sales execution and margins.

Globus Medical NYSE: GMED reported second-quarter 2026 revenue of $789.6 million, up 6% from a year earlier, as growth in its spine and trauma businesses helped offset declines in enabling technologies and Nevro sales. The company reaffirmed its full-year revenue outlook while raising its adjusted earnings forecast, citing margin expansion and operating leverage in the first half. Fully diluted GAAP earnings per share were $1.10, while non-GAAP diluted earnings per share reached a quarterly record of $1.34, up 56% from the prior-year quarter. Adjusted EBITDA margin increased to 35.4% from 28.0% a year earlier.

“We completed an exceptional Q2, positioning us for a strong 2026 as we move into the second half of the year,” President and Chief Executive Officer Keith Pfeil said on the company’s earnings call.

Musculoskeletal revenue totaled $763.5 million, rising 8% year over year and 4% sequentially. Excluding Nevro, the company’s base business grew 9%, led by 7% growth in U.S. spine revenue and 14% reported growth in international spine revenue. Pfeil said U.S. spine growth reflected procedural volumes, competitive sales-force recruiting, robotic pull-through and product launches. The company said competitive hires in the second quarter were double the first-quarter level and represented its second-highest onboarding total in eight quarters. Several U.S. spine products posted double-digit growth, including SABLE, ELSA, HEDRON C, Reline-C and Reline Open, according to management. Its DuraPro power tools product grew more than 250% during the quarter. International spine revenue rose 12% on a constant-currency basis. The company cited mid-teens growth in Italy, Spain and Poland, along with broad-based growth in Asia-Pacific markets and gains in Brazil and Colombia. Pfeil said improved set deliveries and inventory availability supported deeper penetration in markets where Globus already operates.

Trauma revenue increased 31% year over year and 18% sequentially. Management attributed the performance to share gains in its core trauma portfolio and normalized supply for the PRECICE product line, which enabled the company to meet U.S. demand and expand availability in markets outside the United States. The company launched three products in the quarter: the AUTOBAHN Hip Fastener and TENSOR Suture Button System for trauma procedures, as well as Reline 1 for minimally invasive spine procedures.

Enabling Technologies revenue was $26.1 million, down 26% year over year. Chief Financial Officer Kyle Kline said the decline was tied to Globus’ strategy of offering customers more flexible ways to acquire capital equipment rather than relying principally on cash sales.